Nuvectis Pharma (NVCT) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 11, 2026, to be held virtually, with voting on director election and auditor ratification.

• Proxy materials and annual report are available online, with paper copies upon request.

• Record date for voting is April 13, 2026; 27,668,036 shares outstanding.

• Stockholders can vote online, by phone, mail, or during the meeting; proxies may be revoked at any time before voting.

Voting matters and shareholder proposals

• Election of one Class I director (Ron Bentsur) for a three-year term.

• Ratification of Kesselman & Kesselman as independent registered public accounting firm for 2026.

• Stockholders may submit proposals for the 2027 meeting by December 29, 2026.

Board of directors and corporate governance

• Board consists of five directors, divided into three classes; four are independent per Nasdaq standards.

• Board committees: Audit and Compensation; no standing nominating committee, but independent directors recommend nominees.

• Board emphasizes diversity of skills and experience, with a process for stockholder communications.

• Code of Business Conduct and Ethics and Insider Trading Policy in place.